Best Life Sciences Tech Companies in Japan
The 43 best Life Sciences Tech companies in Japan in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Medmain.
- EVERSANA
- LifeSciencesIntelligence
Our analysis of 50 Life Sciences Tech companies
$9.6b in tracked funding; 89% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Tech companies in Japan
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | a-zas A-zas provides marketing and promotional services for pharmaceutical companies. | — | — | Deadpooled | — | 2 | — | — | — |
| 2 | AI Pharma Proprietary AI-based drug discovery platform | — | — | Deadpooled | Hitoshi Hasegawa CEO | — | — | 825 patents Advanced drug formulation and delivery systems for metabolic and inflammatory therapies | — |
| 3 | Alphaya Provider of bioinformatics software solution | — | — | Unfunded | Mohammed Sahli Founder & CEO | — | — | — | — |
| 4 | Bright Core AI-driven platform for drug discovery to extend human healthspan | — | — | Unfunded | Janice Eun Jeong Park Chief Operating Officer & Co-Founder | — | — | — | — |
| 5 | CAGE Software for gene expression analysis | — | — | Unfunded | Koichiro Tsujimaru CEO & President | — | — | — | — |
| 6 | Callisto Provider of a medical image data platform for researchers | — | — | Unfunded | Changhee Han CEO | — | — | — | — |
| 7 | Chrovis Provider of automated genomic intelligence platform | — | — | Unfunded | Kunihiro Nishimura CEO | — | — | — | — |
| 8 | CoLocalization Research Software Software for analysis of fluorescence images | — | — | Unfunded | Vadim Zinchuk Co-Founder | — | — | — | — |
Top 12 Life Sciences Tech companies in Japan
#1
Series A · Minato City, Tokyo · founded 2018$13.3Mraised▾
Provider of AI-based analysis software for pathology image diagnosis. Pidport an AI-based software allows the user's to instantly screen pathological tissues and cells. The pathological image data and case information can be managed and stored on the cloud server.
- May 2025Series A$3.3M
- Apr 2024Series A$5.5M
#2
Seed · Kobe, Hyogo · founded 2024$252.4Kraised▾
Provider of an AI-powered platform automating research workflows for experts. The platform facilitates search, review, and analysis of complex research data. It offers features such as manuscript review, literature review, and information retrieval, enabling users to focus on expert analysis and innovation. The platform aims to reduce time spent on repetitive tasks, thereby increasing productivity.
- Jul 2025Seed$252.4K
#3
Seed · Osaka, Osaka · founded 2024$120Kraised▾
Developer of an AI platform streamlining drug discovery and development. The platform integrates machine learning and computational modeling to accelerate therapeutic development. It leverages deep learning and generative models to transform the drug discovery pipeline. The platform supports target identification, molecular design, and preclinical evaluation. It uncovers novel therapeutics with greater speed, precision, and scalability.
- Aug 2025Seed$120K
#4
Series B · Chiyoda City, Tokyo · founded 2015 · 56 employees$5.6Mraised▾
Provider of integrated genomic analysis platform. The company uses its core algorithm as a core technology for analyzing exhaustive epigenome data obtained from the next-generation sequencer. The company also provides next-generation sequencing data analysis services.
- Aug 2024Series B$3.4M
- Nov 2018Seed$2.2M
#5
Series A · Minato City, Tokyo · founded 2019$4.7Mraised▾
Digital molecular modelling tool for drug development. The company has developed a platform that assists in calculating compound structures, enzymatic reactions, and more. It also has features for enzyme screening, bio-retrosynthesis and more.
- Apr 2024Series A$4.7M
#6
Series C · Tokyo, Tokyo · founded 2013 · 33 employees$11.7Mraised▾
Provider of AI-based platform for drug discovery and design. The company uses Next Generation Sequencing and Molecular Biology technology for the discovery and detection of antibody molecules.
- Aug 2021Series C$7.2M
- Dec 2018Series B$2.5M
- 2016Grant (prize money)—
- Sep 2014Series A$2M
#7
Series A · Tokyo, Tokyo · founded 2017 · 11 employees$5.2Mraised▾
Developer of software for clinical trial patient recruitment. It is focused on services including clinical trial matching service for medical institutions, database construction e-bora society system (PUZZ), mail magazine delivery (SMT) retention service, clinical trial visit management system (PUZZ), clinical trial special web page (PUZZ), waiting report, etc.
- Jul 2022Series A$4.8M
- Feb 2020Seed—
- Dec 2018Seed$450K
#8
Deadpooled · Tokyo, Tokyo · founded 2021$1.6Mraised▾
AI-powered platform to streamline the drug discovery process. The company utilizes the drug discovery platform technology "AI Drug Discovery 3.0", machine learning technology, physics simulation technology, and HPC technology to advance the pipeline and create new drugs.
- Aug 2023Seed$1.6M
#9
Seed · Tokyo, Tokyo · founded 2022$1.5Mraised▾
Provider of a medical image data platform for drug discovery and development. It provides a platform for medical facilities that aggregates medical image datasets such as radiology images, pathological images, clinical information, molecular diagnosis results that can be used immediately for research and development of medical and drug discovery AI.
- Apr 2023Seed$1.5M
#10
Series A · Tokyo, Tokyo · founded 2014 · 35 employees$7Mraised▾
LPixel develops image analysis tools using artificial intelligence. It has two products for life sciences. The first product is a suite of general purpose image management tools that prevents misuse of scientific images, 3D measurement kit for plants, and software for motion tracking, and color analyses. It is also developing an AI-based image analysis tool for the detection of cancer.
- Oct 2016Series A$7M
#11
Series A · Tokyo, Tokyo · founded 2017 · 10 employees$2.3Mraised▾
Socium provides an AI-enabled platform for drug discovery and development. The company helps in searching markers from omics data and clinical information. Their solution helps in finding approved drugs that show medicinal effects on diseases.
- Jul 2021Series A—
- Oct 2018Series A$2.3M
#12
Series A · Tokyo, Tokyo · founded 2015 · 39 employees$4Mraised▾
Developer of a document management platform designed to organize the healthcare and life sciences industry's workflow. The company's platform provides standard modules and cloud services for clinical research and clinical trials to medical institutions and pharmaceutical companies, enabling hospitals, contract research organizations, and medical device firms to optimize the quality in managing clinical documentation and processes.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Japan
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,059 Japan-affiliated papers.
- The University of Tokyo76
- Kyoto University65
- Hokkaido University47
- Tohoku University40
- Korea University36
- Gene5→34
- Antibody1→17
- Transcription (linguistics)1→16
- Cell culture1→14
- Transcription factor3→16
- Gene4→27
- Downregulation and upregulation2→21
- Cell culture1→12
- Immune system1→12
- Transcriptome1→11
- Antibiotic resistance2→4
Where biotechnology is researched across Japan
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in Japan
Japan biotechnology patent filing is accelerating — 64,298 filings from 8,000 assignees (2016–2025), led by Chugai Pharmaceutical, Ajinomoto KK, Daiichi Sankyo; annual filings 5582→6516.
- Chugai Pharmaceutical6259
- Ajinomoto KK4106
- Daiichi Sankyo3211
- UNIV Kyoto2855
- Toray Industries2746
- UNIV Osaka2719
- Takeda Pharmaceuticals2641
- UNIV Tokyo2515
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.